Clinical Trials Directory

Trials / Completed

CompletedNCT05840926

Probiotic S. Salivarius K12 for the Prevention of Upper Respiratory Tract Infection in Nursery-age Children

Possible Prophylactic Role of the S. Salivarius K12 Probiotic Strain for the Upper Respiratory Tract Infection and Nursery-age Children

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
287 (actual)
Sponsor
Liaquat University of Medical & Health Sciences · Academic / Other
Sex
All
Age
1 Year – 3 Years
Healthy volunteers
Accepted

Summary

The purpose of this retrospective study is to assess the treatment benefits of probiotic Streptococcus salivarius K12 for the prevention of recurrent bacterial and viral infections of the pharynx, tonsils and ears in children under 3 years of age.

Detailed description

Recurrent bacterial and viral infections of the pharynx, tonsils and ears are a problem that can affect children of all ages. The persistence of these infections can lead to an overuse of drugs such as antibiotics, antipyretics and anti-inflammatories, with the possible consequent presence of side effects and above all an increase in antibiotic resistance, a global public health issue. In search at reducing the use of antibiotics and antivirals, there is currently a great scientific interest in probiotic therapies for the oral cavity infection. The aim of this retrospective, controlled, multicenter, non-profit study is to evaluate the efficacy and safety of the administration of Streptococcus salivarius K12 in pediatric patients attending the 1st or 2nd year of nursery school (\< 3 years of age ), in the prophylaxis of the most common bacterial or viral respiratory infections, assessing the consequent reduction in the use of antibiotics, antivirals or other therapies compared to children.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTProbiotic Streptococcus salivarius K12Oral 1 billion CFU of Probiotic Streptococcus salivarius K12
OTHERNo probiotic supplementationChildren who did not receive any probiotic supplementation

Timeline

Start date
2022-01-05
Primary completion
2022-12-20
Completion
2023-03-31
First posted
2023-05-03
Last updated
2023-05-03

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT05840926. Inclusion in this directory is not an endorsement.